ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1541732
This article is part of the Research TopicMechanisms of Resistance to Immunotherapy and Targeted Therapy and Predictive Biomarkers in Non-small Cell Lung CancerView all 6 articles
Bioinformatics Analysis Identifies ZBTB16 as a Potential Immune Biomarker for Lung Cancer and Pan-Cancer
Provisionally accepted
- 1The First Affiliated Hospital of Huzhou University, Huzhou, China
- 2Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Lung cancer (LC) is a deadly cancer and a challenging public health problem worldwide. The aim of this study is to use bioinformatics to analyze the potential of ZBTB16 as an immune biomarker in lung cancer and various other cancers.Overlapping differentially expressed genes (DEGs) in LC were selected from GSE3268, GSE1987, GSE31547 and GSE18842 gene expression data sets. We conducted a comprehensive bioinformatics analysis of these differentially expressed genes, aiming to explore their enrichment functions and pathways, relative expression levels, interaction networks, and weighted gene co expression network (WGCNA) module analysis. Then, the potential role of ZBTB16 in the occurrence and progression of lung cancer was verified, and immune invasion analysis, pan-cancer analysis and mRNA-miRNA link analysis were performed.Results: There were 16 genes with increased expression and 100 genes with decreased expression. Among them, KEGG analysis showed that these DEGs were significantly involved in complement and coagulation cascades, as well as related pathways such as proximal tubular bicarbonate recovery.Previous studies have shown that ZBTB16 plays an important role in various systemic tumors, but its function in lung cancer has not been revealed. WGCNA analysis shows that ZBTB16 is significant in lung cancer. Therefore, we will focus our attention on ZBTB16. Then, TCGA database, HPA database, and whole blood qPCR testing were used to verify the differential expression of ZBTB16 in lung cancer, and immune invasion analysis of ZBTB16 in lung cancer, pan cancer analysis of ZBTB16, and mRNA miRNA linkage analysis of ZBTB16 were performed.Three validation methods and pan cancer analysis all showed that the expression of ZBTB16 was reduced in lung cancer and various cancers, which may be a key gene for the occurrence and development of lung cancer and various cancers.
Keywords: lung cancer, immune biomarker, DEGs, WGCNA, TCGA
Received: 08 Dec 2024; Accepted: 26 May 2025.
Copyright: © 2025 Shi, Cai, Zhu, Li and LI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yong LI, The First Affiliated Hospital of Huzhou University, Huzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.